Drug Approval | August 26, 2021
Wockhardt and Jemincare partner for novel respiratory antibiotic Nafithromycin
The company to receive upfront and milestone payments, in addition to royalties
The company to receive upfront and milestone payments, in addition to royalties
The two-year donation supports the development of clinical tests for Covid-19 severity assessment and the focus on the development of simple immunoassays using single molecule counting technology
Domestic business was up 41.9% YoY and 27.7% QoQ
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
The company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Goal of providing 12-month internship opportunities for qualified students
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Subscribe To Our Newsletter & Stay Updated
